ANXA1 and acute myeloid leukemia: To identify novel signaling molecules and therapeutic targets in AML, we performed a study of Gene Expression Profile (GEP) analyses from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) datasets, according to the review of molecular biomarkers in AML.[17] ANXA1 was identified as one of the most highly expressed biomarkers in AML (Figures1A,B and S1, Supporting Information).